+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

MPLS-based Core Networks - Global Strategic Business Report

  • PDF Icon

    Report

  • 297 Pages
  • October 2026
  • Region: Global
  • Market Glass, Inc.
  • ID: 6093850
The global market for MPLS-based Core Networks was valued at US$41.2 Billion in 2025 and is projected to reach US$78.2 Billion by 2032, growing at a CAGR of 9.6% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global MPLS-Based Core Networks Market - Key Trends & Drivers Summarized

Why Are MPLS-Based Core Networks Still Relevant in Today’s Evolving Telecom Infrastructure?

Multiprotocol Label Switching (MPLS) remains a foundational technology in global core networks, despite the growing popularity of SD-WAN and internet-based routing. MPLS enables efficient, high-performance data forwarding by using label-switching rather than traditional IP routing, offering deterministic paths, low latency, and robust quality of service (QoS). It is extensively deployed by telecom carriers and enterprises to support mission-critical applications that require predictable performance - such as VoIP, video conferencing, and data center interconnects.

Core networks based on MPLS continue to dominate due to their ability to handle large-scale, multi-service traffic across geographically distributed networks. Their scalability, traffic engineering capabilities, and security make them ideal for tier-1 ISPs, mobile backhaul, and enterprise VPN deployments. As enterprises adopt hybrid cloud and multi-site configurations, MPLS is often retained for core connectivity, ensuring uptime, congestion control, and SLA adherence.

What Enhancements Are Making MPLS Networks More Agile and Compatible with Next-Gen Services?

MPLS networks are evolving through the integration of newer protocols such as Segment Routing (SR-MPLS), MPLS-TP (Transport Profile), and SDN orchestration. These enhancements allow for better programmability, faster path restoration, and simplified network management. With SR-MPLS, service providers can dynamically define forwarding paths based on application performance requirements - enabling more responsive and cost-efficient routing.

Operators are also integrating MPLS cores with Network Functions Virtualization (NFV) and cloud-native orchestration platforms to automate provisioning and improve resource utilization. MPLS-aware routers are becoming more power-efficient and software-definable, allowing core networks to support increasingly diverse workloads without compromising speed or reliability. As the line between transport and service layers blurs, MPLS remains an enabler of integrated service architectures.

Which Use Cases and Regions Are Maintaining Demand for MPLS Core Infrastructures?

High-density metropolitan regions, national broadband networks, and cross-border telecom routes remain strongholds for MPLS deployment. Enterprise applications - particularly in finance, healthcare, government, and manufacturing - continue to rely on MPLS for private WANs, offering deterministic latency and guaranteed throughput. Telecom operators use MPLS cores to connect access networks, data centers, and cloud gateways, enabling seamless service delivery.

Emerging economies with growing internet penetration and enterprise digitization are upgrading core infrastructure with MPLS to support growing traffic volumes and differentiated services. In areas where fiber is still being rolled out, MPLS-based routing helps manage limited bandwidth more efficiently while preserving critical service performance. Hybrid network topologies combining MPLS with SD-WAN overlays are also rising, particularly in Asia-Pacific, the Middle East, and Latin America.

The Growth in the MPLS-Based Core Networks Market Is Driven by Several Factors

The growth in the MPLS-based core networks market is driven by several factors including continued demand for carrier-grade performance, growth in mission-critical enterprise connectivity, and the modernization of backbone networks in developing regions. Integration with segment routing, SDN, and automation platforms is extending MPLS’s value in next-generation transport architectures. The proliferation of latency-sensitive services, increasing enterprise cloud adoption, and demand for ultra-reliable VPN services are reinforcing the role of MPLS in the global core. While alternative technologies gain traction at the edge, MPLS continues to provide the backbone reliability essential for high-throughput, multi-service network operations.

Report Scope

The report analyzes the MPLS-based Core Networks market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:
  • Segments: Component (MPLS-based Devices, IP / MPLS Management Software, Services); End-Use (BFSI, Manufacturing, Government, Healthcare, IT & Telecommunications, Retail, Other End-Uses)
  • Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the MPLS-based Devices segment, which is expected to reach US$44.1 Billion by 2032 with a CAGR of a 9.1%. The IP / MPLS Management Software segment is also set to grow at 10.9% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, valued at $11.2 Billion in 2025, and China, forecasted to grow at an impressive 14.4% CAGR to reach $17.8 Billion by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global MPLS-based Core Networks Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global MPLS-based Core Networks Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global MPLS-based Core Networks Market expected to evolve by 2032?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2032?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as ADVA Optical Networking, Alcatel-Lucent Enterprise, Arista Networks, AT&T Inc., BICS and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this MPLS-based Core Networks market report include:

  • ADVA Optical Networking
  • Alcatel-Lucent Enterprise
  • Arista Networks
  • AT&T Inc.
  • BICS
  • BT Group plc
  • CenturyLink (Lumen Technologies)
  • Ciena Corporation
  • Cisco Systems, Inc.
  • Colt Technology Services
  • Deutsche Telekom AG
  • Ericsson
  • GTT Communications
  • Huawei Technologies Co., Ltd.
  • Infinera Corporation
  • IPTP Networks
  • Juniper Networks, Inc.
  • Nokia Corporation
  • Orange S.A.
  • Verizon Communications Inc.

What Sets This Report Apart From Others?

  • Grounded in Domain Expert Perspectives: Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.
  • Captures Early Market Signals: Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.
  • Draws From a Broad, Validated Intelligence Base: Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.
  • Connects Signals With Strategic Market Direction: Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.
  • Provides In-Depth Company Intelligence: Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.
  • Market Share Is Examined Where It Matters: A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, the report extends market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
  • World Market Trajectories
  • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
  • Mpox Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Global Incidence of Mpox Infections Spurs Demand for Rapid and Accurate Diagnostic Solutions
  • Government Surveillance Programs and Outbreak Preparedness Plans Drive Adoption of Diagnostic Testing
  • Technological Advancements in Point-of-Care Testing Strengthen Accessibility in Resource-Limited Settings
  • Integration of PCR and Isothermal Amplification Methods Propels Market for Molecular Mpox Diagnostics
  • Public Health Emergency Declarations Throw Spotlight on Fast-Tracking of Diagnostic Product Approvals
  • Expansion of Travel Screening and Quarantine Protocols Generates Demand for Portable Test Kits
  • Increasing Role of Central Laboratories in Outbreak Control Sustains Market for High-Throughput Systems
  • Demand for Cost-Effective Testing Solutions in Developing Nations Fuels Adoption of Lateral Flow Assays
  • Healthcare Worker Safety Protocols Drive Investment in Biosafe Sample Collection and Handling Tools
  • Growth in Zoonotic Disease Surveillance Expands Market Opportunity for Cross-Species Diagnostic Platforms
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Mpox Diagnostics Market Analysis of Annual Sales in US$ Thousand for Years 2020 through 2032
  • Table 2: World Recent Past, Current & Future Analysis for Mpox Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 3: World Historic Review for Mpox Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 4: World 13-Year Perspective for Mpox Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2020, 2026 & 2032
  • Table 5: World Recent Past, Current & Future Analysis for Antigen Detection Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 6: World Historic Review for Antigen Detection Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 7: World 13-Year Perspective for Antigen Detection Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 8: World Recent Past, Current & Future Analysis for Molecular Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 9: World Historic Review for Molecular Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 10: World 13-Year Perspective for Molecular Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 11: World Recent Past, Current & Future Analysis for Urine Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 12: World Historic Review for Urine Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 13: World 13-Year Perspective for Urine Sample by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 14: World Recent Past, Current & Future Analysis for Whole Blood Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 15: World Historic Review for Whole Blood Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 16: World 13-Year Perspective for Whole Blood Sample by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 17: World Recent Past, Current & Future Analysis for Skin Lesion Specimen Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 18: World Historic Review for Skin Lesion Specimen Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 19: World 13-Year Perspective for Skin Lesion Specimen Sample by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
III. MARKET ANALYSIS
UNITED STATES
  • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
  • Table 20: USA Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 21: USA Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 22: USA 13-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2020, 2026 & 2032
  • Table 23: USA Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 24: USA Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 25: USA 13-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2020, 2026 & 2032
CANADA
  • Table 26: Canada Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 27: Canada Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 28: Canada 13-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2020, 2026 & 2032
  • Table 29: Canada Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 30: Canada Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 31: Canada 13-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2020, 2026 & 2032
JAPAN
  • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
  • Table 32: Japan Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 33: Japan Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 34: Japan 13-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2020, 2026 & 2032
  • Table 35: Japan Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 36: Japan Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 37: Japan 13-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2020, 2026 & 2032
CHINA
  • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
  • Table 38: China Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 39: China Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 40: China 13-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2020, 2026 & 2032
  • Table 41: China Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 42: China Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 43: China 13-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2020, 2026 & 2032
EUROPE
  • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
  • Table 44: Europe Recent Past, Current & Future Analysis for Mpox Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 45: Europe Historic Review for Mpox Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 46: Europe 13-Year Perspective for Mpox Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2020, 2026 & 2032
  • Table 47: Europe Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 48: Europe Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 49: Europe 13-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2020, 2026 & 2032
  • Table 50: Europe Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 51: Europe Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 52: Europe 13-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2020, 2026 & 2032
FRANCE
  • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
  • Table 53: France Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 54: France Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 55: France 13-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2020, 2026 & 2032
  • Table 56: France Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 57: France Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 58: France 13-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2020, 2026 & 2032
GERMANY
  • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
  • Table 59: Germany Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 60: Germany Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 61: Germany 13-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2020, 2026 & 2032
  • Table 62: Germany Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 63: Germany Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 64: Germany 13-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2020, 2026 & 2032
ITALY
  • Table 65: Italy Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 66: Italy Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 67: Italy 13-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2020, 2026 & 2032
  • Table 68: Italy Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 69: Italy Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 70: Italy 13-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2020, 2026 & 2032
UNITED KINGDOM
  • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
  • Table 71: UK Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 72: UK Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 73: UK 13-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2020, 2026 & 2032
  • Table 74: UK Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 75: UK Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 76: UK 13-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2020, 2026 & 2032
SPAIN
  • Table 77: Spain Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 78: Spain Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 79: Spain 13-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2020, 2026 & 2032
  • Table 80: Spain Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 81: Spain Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 82: Spain 13-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2020, 2026 & 2032
RUSSIA
  • Table 83: Russia Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 84: Russia Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 85: Russia 13-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2020, 2026 & 2032
  • Table 86: Russia Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 87: Russia Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 88: Russia 13-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2020, 2026 & 2032
REST OF EUROPE
  • Table 89: Rest of Europe Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 90: Rest of Europe Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 91: Rest of Europe 13-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2020, 2026 & 2032
  • Table 92: Rest of Europe Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 93: Rest of Europe Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 94: Rest of Europe 13-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2020, 2026 & 2032
ASIA-PACIFIC
  • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2026 (E)
  • Table 95: Asia-Pacific Recent Past, Current & Future Analysis for Mpox Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 96: Asia-Pacific Historic Review for Mpox Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 97: Asia-Pacific 13-Year Perspective for Mpox Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2020, 2026 & 2032
  • Table 98: Asia-Pacific Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 99: Asia-Pacific Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 100: Asia-Pacific 13-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2020, 2026 & 2032
  • Table 101: Asia-Pacific Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 102: Asia-Pacific Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 103: Asia-Pacific 13-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2020, 2026 & 2032
AUSTRALIA
  • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2026 (E)
INDIA
  • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2026 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2026 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2026 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2026 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • ADVA Optical Networking
  • Alcatel-Lucent Enterprise
  • Arista Networks
  • AT&T Inc.
  • BICS
  • BT Group plc
  • CenturyLink (Lumen Technologies)
  • Ciena Corporation
  • Cisco Systems, Inc.
  • Colt Technology Services
  • Deutsche Telekom AG
  • Ericsson
  • GTT Communications
  • Huawei Technologies Co., Ltd.
  • Infinera Corporation
  • IPTP Networks
  • Juniper Networks, Inc.
  • Nokia Corporation
  • Orange S.A.
  • Verizon Communications Inc.

Table Information